Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Travoprost APS vs Xalatan in Glaucoma and Ocular Hypertension
NCT00892762Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jun 2009
- Primary completion
- May 2011
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: National Eye Institute Visual Function Questionnaire-25 at 90 days. Started Jun 2009; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00892762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00892762.